1. 40P Can we predict which TIL products will react against NSCLC tumours based on the immune infiltrates?. (December 2022) Authors: Castenmiller, S.; Kanagasabesan, N.; de Groot, R.; Guislain, A.; van Loenen, M.; Monkhorst, K.; Hartemink, K.; Klomp, H.M.; Smit, E.; Haanen, J.B.A.G.; Wolkers, M. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. (December 2019) Authors: Thunnissen, E.; Lissenberg-Witte, B.I.; van den Heuvel, M.M.; Monkhorst, K.; Skov, B.G.; Sørensen, J.B.; Mellemgaard, A.; Dingemans, A.M.C.; Speel, E.J.M.; de Langen, A.J.; Hashemi, S.M.S.; Bahce, I.; van der Drift, M.A.; Looijen-Salamon, M.G.; Gosney, J.; Postmus, P.E.; Samii, S.M.S.; Duplaquet,... Journal: Lung cancer Issue: Volume 138(2019) Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments. (September 2022) Authors: Castenmiller, S.M.; de Groot, R.; Guislain, A.; Monkhorst, K.; Hartemink, K.J.; Veenhof, A.A.F.A.; Smit, E.F.; Haanen, J.B.A.G.; Wolkers, M.C. Journal: Immuno-oncology technology Issue: Volume 15(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. (March 2020) Authors: van Veggel, B.; Madeira R Santos, J.F. Vilacha; Hashemi, S.M.S.; Paats, M.S.; Monkhorst, K.; Heideman, D.A.M.; Groves, M.; Radonic, T.; Smit, E.F.; Schuuring, E.; van der Wekken, A.J.; de Langen, A.J. Journal: Lung cancer Issue: Volume 141(2020) Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The force of HER2 – A druggable target in NSCLC?. (June 2020) Authors: Jebbink, M.; de Langen, A.J.; Boelens, M.C.; Monkhorst, K.; Smit, E.F. Journal: Cancer treatment reviews Issue: Volume 86(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer. (November 2021) Authors: Joosten, P.J.M.; de Langen, A.J.; van der Noort, V.; Monkhorst, K.; Klomp, H.M.; Veenhof, A.A.F.A.; Dickhoff, C.; Smit, E.F.; Hartemink, K.J. Journal: Lung cancer Issue: Volume 161(2021) Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗